Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. From the reaction to Aduhelm's approval and option chain data, we see that the current stock ...

Data from Biogen's confirmatory Phase 3 study of its latest Alzheimer's candidate, Lecanemab, was released yesterday evening, and the headline news is that Lecanemab met its primary endpoint of ...

Arguably more important to the company’s future is the regulatory pathway and commercial preparations for Alzheimer’s hopeful lecanemab. Last month, Biogen and partner Eisai reported top-line Phase 3 ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

Lecanemab is the first amyloid-targeting drug ... watched by patient advocates and scientists alike because Eisai and Biogen's drug, sold under the brand name Leqembi, is the first beta amyloid ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

The Food and Drug Administration granted accelerated approval for lecanemab, a drug developed by Biogen and Eisai which has been found to slow cognitive decline in some patients with Azheimer’s ...

11 After lecanemab received full approval, CMS confirmed it would offer broader Medicare coverage. 12 Eisai and Biogen listed lecanemab at $26,500 a year, less than either of aducanumab’s price ...

The federal agency decided Friday to grant accelerated approval to lecanemab, an intravenous injection developed by the Japanese biopharma company Eisai and the American manufacturer Biogen.

Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing. By Rebecca Robbins and Pam Belluck The pharmaceutical companies Biogen and ...

The new drug, called lecanemab, could be safer and provide more obvious benefits than its controversial predecessor, and Biogen expects results from an advanced clinical trial this fall.

Patients taking the drug, known as lecanemab, showed a 27% decrease in cognitive decline compared to a control group, according to developers Biogen, based in Cambridge, Massachusetts, and Eisai ...